icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
June 23-26 2021
Back grey_arrow_rt.gif
 
 
 
Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir
in Patients With Signs of Portal Hypertension

 
 
  EASL 2021 Presented at The International Liver Congress (EASL), 23-26 June 202
 
RS Brown Jr1, MA Collins2, A Emmett2, A Topp2, M Burroughs2, R Ferreira2, JJ Feld3 1Center for Liver Disease and Transplantation, Weill Cornell Medical College, New York, New York, United States; 2AbbVie Inc., North Chicago, Illinois, United States; 3Toronto Centre for Liver Disease, University Health Network, University of Toronto, Toronto, Ontario, Canada

0623211

0623212

0623213

0623214

0623215

0623216

0623217